The 2009 ACVIM guidelines encouraged veterinarians to add VETMEDIN to their standard treatment for CHF in dogs. The experts agreed that VETMEDIN should be used at the start of clinical signs (known as Stage C).
The recommended standard treatment for dogs with CHF should include:
VETMEDIN is a versatile, first-line therapy for the treatment of CHF due to AVVI or DCM.7
Important safety information: VETMEDIN should not be given in case of hypertrophic cardiomyopathy, aortic stenosis, or any other clinical condition where an augmentation of cardiac output is inappropriate for functional or anatomical reasons. The safety of VETMEDIN has not been established in dogs with asymptomatic heart disease or in heart failure caused by etiologies other than atrioventricular valvular insufficiency or dilated cardiomyopathy. Use only in dogs with clinical evidence of heart failure. The most common side effects reported in field studies were poor appetite, lethargy, diarrhea, dyspnea, azotemia, weakness, and ataxia. If side effects should occur, pet owners should contact their veterinarian. Please refer to the Full Prescribing Information here.
VETMEDIN is a registered trademark of Boehringer Ingelheim Vetmedica GmbH, licensed to Boehringer Ingelheim Vetmedica, Inc.